• 1
    Oh WK, Hurwitz M, D’Amico AV, Richie JP, Kantoff PW. Neoplasms of the prostate. In KufeDW, PollockRE, WeichselbaumRR et al., eds, Holland-Frei Cancer Medicine, Chap. 111, 6th edn. Hamilton, Ontario, Canada: Decker Inc., 2003: 170740
  • 2
    Paweletz CP, Liotta LA, Petricoin EF. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 2001; 57 (Suppl. 4A): 1603
  • 3
    Wang S, Diamond DL, Hass GM, Sokoloff R, Vessella RL. Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107–1A4 by protein chip array, surface-enhanced laser desorption/ionization (SELDI) technology. Int J Cancer 2001; 92: 8716
  • 4
    Xiao Z, Adam BL, Cazares LH et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001; 61: 602933
  • 5
    Petricoin E, F3 Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 15768
  • 6
    Roboz J, Ma L, Sung M, Holland JF. Protein profiles in colon cancer by SELDI-TOF mass spectrometry. Proc AACR 2002; 43: 37
  • 7
    Dolios G, Roboz J, Wang R. Identification of colon cancer associating protein in plasma using MALDI-TOF mass spectrometry. Presented at the 51st ASMS Conference on Mass Spectrometry, 2003